Loading clinical trials...

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT04996797

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC). After the completion of the 12-week induction...

Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)•29 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

RECRUITING

Association Between LRG and Histologic Remission in Ulcerative Colitis

NCT06372613 · Ulcerative Colitis in Histologic Remission

RECRUITINGPhase 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

NCT07550673 · Acute Severe Ulcerative Colitis

RECRUITINGPhase 1/2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471 · Ulcerative Colitis (UC)

RECRUITINGPhase 1/2

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

NCT06071312 · Clostridium Difficile, Ulcerative Colitis

RECRUITINGPhase 1/2

Superdonor FMT in Patients With Ulcerative Colitis

NCT05739864 · Active Ulcerative Colitis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 6, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment178

Start dateJul 2021

Last updatedAug 6, 2025

Condition

Ulcerative Colitis

Locations shown

Prometheus Biosciences Selected Center

Mobile, Alabama

Prometheus Biosciences Selected Site

Phoenix, Arizona

Prometheus Biosciences Selected Site

Sun City, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Association Between LRG and Histologic Remission in Ulcerative Colitis

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach

Superdonor FMT in Patients With Ulcerative Colitis

Trial snapshot

Condition

Locations shown

For caregivers